IDH1-MUTANT prostate cancer may represent a distinct molecular subtype of the disease, showing unexpectedly favourable survival outcomes despite frequent high-grade and high-stage presentation, according to a multi-institutional retrospective analysis.
Prostate cancer is the most common urological malignancy in men and can range from slow-growing disease to rapidly progressive metastatic cancer. The rare IDH1-mutant tumours often displayed aggressive pathological characteristics at diagnosis yet were linked to improved survival outcomes compared with matched controls.
Distinct Molecular Profile in IDH1-Mutant Disease
IDH enzymes regulate cellular metabolism, and mutations are thought to drive metabolic disruption alongside epigenetic and transcriptional changes.
The study identified 99 cases with IDH1 mutations and 12 cases with IDH2 mutations using genomics databases across multiple institutions. 91% of patients presented with localised disease. Adverse pathological features were common, with T3 stage in 42% of cases, and grade group 5 disease in 54%.
Compared with matched controls, patients with IDH1-mutant tumours demonstrated significantly improved outcomes, including longer overall survival, metastasis-free survival and progression-free survival during hormonal therapy.
Molecular profiling revealed a distinct genomic landscape. IDH1-mutant tumours were enriched for activating FOXA1 and CTNNB1 mutations, while tending to lack TMPRSS2-ERG fusions, SPOP mutations and RB1 alterations. Transcriptional analysis showed evidence of global gene repression alongside metabolic and epigenetic reprogramming.
IDH1 – Aggressive Histology but Favourable Clinical Outcomes
Despite high-grade pathology at presentation, the clinical course of IDH1-mutant prostate cancer appeared more favourable than that of IDH1-wild-type tumours in matched controls. This suggests that tumour metabolism may play an important role in shaping disease progression in this subgroup.
It is important to note that survival analyses were reported for IDH1 cases only; no outcome data were presented for IDH2-mutant disease, which limits interpretation of its prognostic significance.
Implications for Prostate Cancer Biology and Treatment
The study adds to evidence that the prognostic impact of IDH mutations varies across cancer types. In glioma, IDH mutations are typically linked to improved outcomes, while in acute myeloid leukaemia and cholangiocarcinoma they are often associated with poorer prognosis.
Researchers suggested that androgen receptor signalling in prostate cancer, which can regulate IDH1 expression, may contribute to the distinct biological behaviour observed in this subtype.
Although retrospective in design, the findings indicate that IDH1-mutant prostate cancer may represent a biologically and clinically distinct entity. This could inform future research into prostate cancer metabolism and potential therapeutic targeting strategies in molecularly selected patients.
Reference
Cavka L et al. IDH1 Mutations are associated with favorable outcomes in prostate cancer. Eur Urol. 2026;DOI:10.1016/j.eururo.2026.03.014.
Featured image: ActionGP on Adobe Stock
